Published in Gene Therapy Weekly, October 26th, 2006
Cenix will apply its well-established expertise combining high throughput (HT), genome-scale screening applications of RNAi with high content phenotypic analyses in cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
By yielding direct and highly predictive insights into the cellular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly